Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms

Addiction
Damaris J RohsenowPeter M Monti

Abstract

Varenicline was compared with transdermal nicotine (NRT) for smokers with current substance use disorders (SUD) for effects on 3-month smoking abstinence (primary outcome) and, secondarily, on 3- and 6 month abstinence while adjusting for medication adherence, and on additional smoking and substance use outcomes. Moderation by major depressive disorder history (MDD) and adherence were investigated. Double-blind double-placebo-controlled randomized design, stratifying by MDD, gender and nicotine dependence, with 3 and 6 months follow-up. University offices in Rhode Island, USA. Adult smokers (n = 137), in SUD treatment, substance abstinent <12 months (n = 77 varenicline, 60 NRT). Twelve weeks of varenicline (2 mg/day, after 1-week dose run-up) or NRT (21 mg/day decreasing to 7 mg/day). Primary: point-prevalence smoking abstinence (7-day, confirmed) at 3 months. Secondary: point-prevalence abstinence at 6 months, quantity and frequency of smoking and substance use at 3 and 6 months, and within-treatment abstinence, medication adherence and depressive symptoms. Smoking outcome analyses were repeated controlling for adherence and investigating adherence as a moderator. Effects on 3-month abstinence were P < 0.065 without a covariat...Continue Reading

Associated Clinical Trials

Sep 22, 2008·Damaris J. Rohsenow, Ph.D., Damaris J. Rohsenow, Ph.D.

References

Sep 1, 1991·British Journal of Addiction·T F HeathertonK O Fagerström
Jan 1, 1989·Health Education Quarterly·V J StrecherK D Monaco
Dec 1, 1994·Journal of Studies on Alcohol. Supplement·R L StoutF K Del Boca
Apr 1, 1993·Annals of Internal Medicine·J F HollisA Biglan
Mar 1, 1993·Journal of Substance Abuse Treatment·J R Hughes
Jan 8, 2000·Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine·J T HaysM C Fiore
Feb 24, 2001·American Journal of Public Health·K P RichterK H Schmelzle
Mar 30, 2002·Alcoholism, Clinical and Experimental Research·Barbara A FlanneryRaye Z Litten
May 15, 2003·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·John R HughesGary E Swan
Nov 30, 2005·Drug and Alcohol Dependence·Rosemarie A MartinPeter M Monti
Jul 6, 2006·JAMA : the Journal of the American Medical Association·David GonzalesUNKNOWN Varenicline Phase 3 Study Group
Jul 6, 2006·JAMA : the Journal of the American Medical Association·Douglas E JorenbyUNKNOWN Varenicline Phase 3 Study Group
Jul 12, 2008·American Journal of Preventive Medicine·UNKNOWN Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff
Mar 3, 2009·Biological Psychiatry·Sherry A McKeeErika Balchunas
Feb 26, 2011·Journal of Substance Abuse Treatment·Maria Caterina GrassiPaolo Nencini
May 12, 2011·Psychopharmacology·Thomas H BrandonBrent J Small
Jun 2, 2012·Physiotherapy Canada. Physiothérapie Canada
Jun 15, 2012·Journal of Psychopharmacology·Rebecca L AshareAndrew A Strasser
Sep 20, 2012·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Kenneth A PerkinsNancy C Jao
Jun 4, 2013·Journal of Addiction Medicine·Raye Z LittenUNKNOWN NCIG (National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group) Study Group
Jun 4, 2013·The Cochrane Database of Systematic Reviews·Kate CahillTim Lancaster
Nov 12, 2013·Journal of Substance Abuse Treatment·Damaris J RohsenowRobert M Swift
Jun 4, 2014·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Karen L CropseyPeter S Hendricks
Mar 13, 2015·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Philip H SmithSherry A McKee
Mar 26, 2015·Journal of Substance Abuse Treatment·Damaris J RohsenowPeter M Monti
Jun 13, 2015·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Sarah L ThurgoodLeonie S Brose
Sep 15, 2015·Alcoholism, Clinical and Experimental Research·Andrea H WeinbergerRenee D Goodwin
Oct 9, 2015·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Sherry A McKeeAndrea H Weinberger
Mar 17, 2016·Journal of Substance Abuse Treatment·Rosemarie A MartinDamaris J Rohsenow

❮ Previous
Next ❯

Citations

Feb 23, 2018·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Neal DoranRobert M Anthenelli
Sep 28, 2017·Journal of Psychoactive Drugs·Tangeria R AdamsShadi Nahvi
Mar 1, 2019·Alcoholism, Clinical and Experimental Research·Krysten W BoldStephanie S O'Malley
Feb 29, 2020·CNS Drugs·Cynthia VladShadi Nahvi
Jul 15, 2020·American Journal of Respiratory and Critical Care Medicine·Frank T LeoneHarold J Farber
Oct 15, 2020·Annals of the American Thoracic Society·Panagis GaliatsatosCarey C Thomson
Feb 17, 2021·Drug and Alcohol Dependence·Joshua L KarelitzKaren L Cropsey

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.